Brandywine Managers’s Ionis Pharmaceuticals IONS Stock Holding History

Brandywine Managers’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,460	Closed	-$374K	–	38
2022 Q3	$374K	Hold	8,460	–	–	1.23%	26
2022 Q2	$313K	Hold	8,460	–	–	0.77%	30
2022 Q1	$313K	Hold	8,460	–	–	0.54%	36
2021 Q4	$257K	Hold	8,460	–	–	0.29%	42
2021 Q3	$284K	Hold	8,460	–	–	0.3%	41
2021 Q2	$337K	Buy	8,460 +1,375	+19%	+$53.9K	0.38%	40
2021 Q1	$319K	Buy	+7,085	New	+$395K	0.42%	41
2019 Q2	–	Sell	-2,500	Closed	-$203K	–	49
2019 Q1	$203K	Buy	+2,500	New	+$161K	0.08%	47

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Brandywine Managers's IONS Position: Q4 2022 in Review

Brandywine Managers sold out of Ionis Pharmaceuticals (IONS) in Q4 2022, closing a stake of 8,460 shares — an estimated $374K sold.

Brandywine Managers first reported a position in IONS in Q1 2019 and held it in 8 quarters. The position peaked at $374K in Q3 2022. 338 funds tracked by Wall St. Rank hold IONS as of Q4 2022.

Brandywine Managers reported no remaining Ionis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Brandywine Managers sold 8,460 Ionis Pharmaceuticals shares in Q4 2022, an estimated $374K.
Brandywine Managers first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 8 quarters.
Brandywine Managers's Ionis Pharmaceuticals position peaked at $374K in Q3 2022.
338 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2022.

Based on Brandywine Managers's 13F filing for Q4 2022, filed 14 Feb 2023.